Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin + Metformin Extension Study in Type 2 Diabetes
NCT00138515Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novartis. Primary endpoints: Safety of vildagliptin in combination with metformin at 52 weeks and Change from baseline in HbA1c at 52 weeks. Started Nov 2004; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00138515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138515.